Next generation imaging in advanced prostate cancer
Next generation imaging (NGI) techniques, particularly PSMA-PETCT and whole body MRI (WB-MRI), are transforming the diagnosis and management of advanced prostate cancer (APC). Traditional imaging methods like bone scans and CT often fall short due to low sensitivity, high false-positive rates and limited ability to detect soft tissue or marrow-based metastases. NGI addresses these limitations by offering superior accuracy in detecting microscopic and early-stage metastatic disease.
PSMA-PETCT demonstrates significantly higher sensitivity and specificity compared to conventional imaging, while WB-MRI excels in identifying bone metastases and monitoring treatment response through advanced metrics like ADC and fat fraction. These technologies not only improve staging and treatment planning but also guide targeted biopsies and enable personalised therapy.
Clinical case studies illustrate NGI’s role in refining radiotherapy, detecting subtle disease progression and evaluating treatment efficacy even when PSA levels remain low. However, challenges remain, including limited access, high costs and the need for specialised training. Current NICE guidelines have yet to fully endorse NGI, pending further evidence of long-term clinical benefit.
Despite these hurdles, NGI holds great promise for revolutionising APC care, offering more precise, responsive and individualised treatment strategies.
To download and read this article as a pdf please sign up to our newsletter.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.
